skip to main content
Idioma:
Resultados 1 2 3 4 5 next page
Refinado por: Nome da Publicação: Annals Of Oncology remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Epigenetic modulations and lineage plasticity in advanced prostate cancer
Epigenetic modulations and lineage plasticity in advanced prostate cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

Epigenetic modulations and lineage plasticity in advanced prostate cancer

Ge, R. ; Wang, Z. ; Montironi, R. ; Jiang, Z. ; Cheng, M. ; Santoni, M. ; Huang, K. ; Massari, F. ; Lu, X. ; Cimadamore, A. ; Lopez-Beltran, A. ; Cheng, L.

Annals of oncology, 2020-04, Vol.31 (4), p.470-479 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
2
Overexpression of CXCL1 and its receptor CXCR2 promote tumor invasion in gastric cancer
Overexpression of CXCL1 and its receptor CXCR2 promote tumor invasion in gastric cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

Overexpression of CXCL1 and its receptor CXCR2 promote tumor invasion in gastric cancer

Cheng, W.-L. ; Wang, C.-S. ; Huang, Y.-H. ; Tsai, M.-M. ; Liang, Y. ; Lin, K.-H.

Annals of oncology, 2011-10, Vol.22 (10), p.2267-2276 [Periódico revisado por pares]

Oxford: Elsevier Ltd

Texto completo disponível

Citações Citado por
3
VP10-2021: Cabozantinib (C) plus atezolizumab (A) versus sorafenib (S) as first-line systemic treatment for advanced hepatocellular carcinoma (aHCC): Results from the randomized phase III COSMIC-312 trial
VP10-2021: Cabozantinib (C) plus atezolizumab (A) versus sorafenib (S) as first-line systemic treatment for advanced hepatocellular carcinoma (aHCC): Results from the randomized phase III COSMIC-312 trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

VP10-2021: Cabozantinib (C) plus atezolizumab (A) versus sorafenib (S) as first-line systemic treatment for advanced hepatocellular carcinoma (aHCC): Results from the randomized phase III COSMIC-312 trial

Kelley, R.K. ; Yau, T. ; Cheng, A.-L. ; Kaseb, A. ; Qin, S. ; Zhu, A.X. ; Chan, S. ; Sukeepaisarnjaroen, W. ; Breder, V. ; Verset, G. ; Gane, E. ; Borbath, I. ; Gomez Rangel, J.D. ; Merle, P. ; Benzaghou, F.M. ; Banerjee, K. ; Hazra, S. ; Fawcett, J. ; Rimassa, L.

Annals of oncology, 2022-01, Vol.33 (1), p.114-116 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível

Citações Citado por
4
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
Material Type:
Artigo 		Adicionar ao Meu Espaço

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO

Chen, L.-T. ; Martinelli, E. ; Cheng, A.-L. ; Pentheroudakis, G. ; Qin, S. ; Bhattacharyya, G.S. ; Ikeda, M. ; Lim, H.-Y. ; Ho, G.F. ; Choo, S.P. ; Ren, Z. ; Malhotra, H. ; Ueno, M. ; Ryoo, B.-Y. ; Kiang, T.C. ; Tai, D. ; Vogel, A. ; Cervantes, A. ; Lu, S.-N. ; Yen, C.-J. ; Huang, Y.-H. ; Chen, S.-C. ; Hsu, C. ; Shen, Y.-C. ; Tabernero, J. ; Yen, Y. ; Hsu, C.-H. ; Yoshino, T. ; Douillard, J.-Y.

Annals of oncology, 2020-03, Vol.31 (3), p.334-351 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
5
LBA35 Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A randomized, phase III trial
LBA35 Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A randomized, phase III trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

LBA35 Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A randomized, phase III trial

Qin, S. ; Chan, L.S. ; Gu, S. ; Bai, Y. ; Ren, Z. ; Lin, X. ; Chen, Z. ; Jia, W. ; Jin, Y. ; Guo, Y. ; Sultanbaev, A.V. ; Pazgan-Simon, M. ; Pisetska, M. ; Liang, X. ; Chen, C. ; Nie, Z. ; Wang, L. ; Cheng, A-L. ; Kaseb, A. ; Vogel, A.

Annals of oncology, 2022-09, Vol.33, p.S1401-S1402 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
6
Multidisciplinary clinic approach improves overall survival outcomes of patients with metastatic germ-cell tumors
Multidisciplinary clinic approach improves overall survival outcomes of patients with metastatic germ-cell tumors
Material Type:
Artigo 		Adicionar ao Meu Espaço

Multidisciplinary clinic approach improves overall survival outcomes of patients with metastatic germ-cell tumors

Albany, C. ; Adra, N. ; Snavely, A.C. ; Cary, C. ; Masterson, T.A. ; Foster, R.S. ; Kesler, K. ; Ulbright, T.M. ; Cheng, L. ; Chovanec, M. ; Taza, F. ; Ku, K. ; Brames, M.J. ; Hanna, N.H. ; Einhorn, L.H.

Annals of oncology, 2018-02, Vol.29 (2), p.341-346 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
7
61P - Autophagy inhibition enhances leflunomide-induced cytotoxicity in human bladder cancer cells
61P - Autophagy inhibition enhances leflunomide-induced cytotoxicity in human bladder cancer cells
Material Type:
Artigo 		Adicionar ao Meu Espaço

61P - Autophagy inhibition enhances leflunomide-induced cytotoxicity in human bladder cancer cells

Cheng, L.

Annals of oncology, 2019-10, Vol.30, p.v17-v17 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível

Citações Citado por
8
Autophagy inhibition enhances leflunomide-induced cytotoxicity in human bladder cancer cells
Autophagy inhibition enhances leflunomide-induced cytotoxicity in human bladder cancer cells
Material Type:
Artigo 		Adicionar ao Meu Espaço

Autophagy inhibition enhances leflunomide-induced cytotoxicity in human bladder cancer cells

Cheng, L.

Annals of oncology, 2019-10, Vol.30, p.v17 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
9
Outcomes by baseline alpha-fetoprotein (AFP) levels in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (HCC)
Outcomes by baseline alpha-fetoprotein (AFP) levels in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (HCC)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Outcomes by baseline alpha-fetoprotein (AFP) levels in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (HCC)

Kelley, R.K. ; El-Khoueiry, A.B. ; Meyer, T. ; Rimassa, L. ; Merle, P. ; Chan, S.L. ; Tran, A. ; Parnis, F. ; Tam, V.C. ; Cattan, S. ; Markby, D.W. ; Clary, D.O. ; Cheng, A.-L. ; Abou-Alfa, G.K.

Annals of oncology, 2018-10, Vol.29, p.viii236-viii236 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
10
Practice patterns, radiologic tumor response, and deterioration of liver function after transarterial chemoembolization (TACE): Final analysis of OPTIMIS in Korea and other regions
Practice patterns, radiologic tumor response, and deterioration of liver function after transarterial chemoembolization (TACE): Final analysis of OPTIMIS in Korea and other regions
Material Type:
Artigo 		Adicionar ao Meu Espaço

Practice patterns, radiologic tumor response, and deterioration of liver function after transarterial chemoembolization (TACE): Final analysis of OPTIMIS in Korea and other regions

Heo, J. ; Cheng, A.-L. ; Raoul, J.-L. ; Peck-Radosavljevic, M. ; Kudo, M. ; Nakajima, K. ; Bayh, I. ; Lin, S.-M. ; Lee, H.C.

Annals of oncology, 2018-11, Vol.29, p.ix47-ix48 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
Resultados 1 2 3 4 5 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.